Fig. 6
From: Immune checkpoint inhibitors for multiple myeloma immunotherapy
“Broad-spectrum” treatment can be used in the beginning of treatment without clear specific immune pathogenesis to provide an initial comprehensive or generalized approach for processes that can cause MM immune disorders, such as adenosine axis, inflammatory cytokine storm, and tumor metabolites.While “narrow-spectrum” therapy can target to relevant cells after clarifying the mechanisms of immune abnormalities